Deregulated Expression of Fat and Muscle Genes in B-Cell Chronic Lymphocytic Leukemia with High Lipoprotein Lipase Expression
Leukemia (2006) 20, 1080–1088 & 2006 Nature Publishing Group All rights reserved 0887-6924/06 $30.00 www.nature.com/leu ORIGINAL ARTICLE Deregulated expression of fat and muscle genes in B-cell chronic lymphocytic leukemia with high lipoprotein lipase expression M Bilban1,2,8, D Heintel3,8, T Scharl4, T Woelfel4, MM Auer2,3, E Porpaczy3, B Kainz3, A Kro¨ber5, VJ Carey6, M Shehata2,3, C Zielinski2, W Pickl7, S Stilgenbauer5, A Gaiger2,3,6, O Wagner1,2,UJa¨ger2,3 and the German CLL Study Group 1Department of Laboratory Medicine, Medical University of Vienna, Vienna, Austria; 2Ludwig Boltzmann Institute for Clinical and Experimental Oncology, Vienna, Austria; 3Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna; Vienna, Austria; 4Department of Statistics and Probability Theory, Vienna University of Technology, Vienna, Austria; 5Department of Internal Medicine III, University of Ulm, Ulm, Germany; 6Department of Medicine, Harvard Medical School, Boston, MA, USA and 7Institute of Immunology, Medical University of Vienna, Vienna, Austria Lipoprotein lipase (LPL) is a prognostic marker in B-cell studies was the identification of a novel prognostic marker, the chronic lymphocytic leukemia (B-CLL) related to immunoglo- ZAP-70 protein, which has already entered routine diagnos- bulin VH gene (IgVH)mutational status. We determined gene tics.3,4,9,26–31 However, microarray analysis has identified a expression profiles using Affymetrix U133A GeneChips in two groups of B-CLLs selected for either high (‘LPL þ ’, n ¼ 10) or number of other potential prognostic or therapeutic targets that low (‘LPLÀ’, n ¼ 10) LPL mRNA expression.
[Show full text]